首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Tnf |
| Uniprot No | Q9Y4K3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-522aa |
| 氨基酸序列 | MSLLNCENSCGSSQSESDCCVAMASSCSAVTKDDSVGGTASTGNLSSSFMEEIQGYDVEFDPPLESKYECPICLMALREAVQTPCGHRFCKACIIKSIRDAGHKCPVDNEILLENQLFPDNFAKREILSLMVKCPNEGCLHKMELRHLEDHQAHCEFALMDCPQCQRPFQKFHINIHILKDCPRRQVSCDNCAASMAFEDKEIHDQNCPLANVICEYCNTILIREQMPNHYDLDCPTAPIPCTFSTFGCHEKMQRNHLARHLQENTQSHMRMLAQAVHSLSVIPDSGYISEVRNFQETIHQLEGRLVRQDHQIRELTAKMETQSMYVSELKRTIRTLEDKVAEIEAQQCNGIYIWKIGNFGMHLKCQEEEKPVVIHSPGFYTGKPGYKLCMRLHLQLPTAQRCANYISLFVHTMQGEYDSHLPWPFQGTIRLTILDQSEAPVRQNHEEIMDAKPELLAFQRPTIPRNPKGFGYVTFMHLEALRQRTFIKDDTLLVRCEVSTRFDMGSLRREGFQPRSTDAGV |
| 预测分子量 | 59.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNF重组蛋白的3条参考文献及其简要摘要：
---
1. **"Human tumor necrosis factor: Production, purification, and characterization"**
**作者**: Aggarwal, B.B., et al. (1985)
**摘要**: 该研究首次报道了通过重组DNA技术在大肠杆菌中表达人类TNF-α，并详细描述了其纯化过程、生物活性鉴定(如细胞毒性分析)以及初步的结构特征，为后续TNF功能研究奠定了基础。
---
2. **"The structure of tumor necrosis factor-alpha at 2.6 Å resolution"**
**作者**: Eck, M.J., & Sprang, S.R. (1989)
**摘要**: 通过X射线晶体学解析了重组TNF-α的三维结构，揭示了其同源三聚体构象及受体结合的关键位点，为理解TNF信号传导机制和靶向药物设计提供了结构基础。
---
3. **"TNF-alpha in cancer therapy: Molecular insights, antitumor effects, and clinical utility"**
**作者**: Balkwill, F. (2002)
**摘要**: 综述了TNF-α在肿瘤微环境中的双重作用(促肿瘤与抗肿瘤)，讨论了重组TNF蛋白在局部治疗(如肢体灌注疗法)中的应用潜力及优化策略，强调其剂量依赖性效应。
---
4. **"Binding and functional comparisons of two types of tumor necrosis factor antagonists"**
**作者**: Scallon, B.J., et al. (2002)
**摘要**: 比较了重组可溶性TNF受体(如依那西普)与抗TNF单克隆抗体(如英夫利昔单抗)的结合特性及中和活性，为临床选择TNF抑制剂提供了实验依据。
---
以上文献涵盖TNF重组蛋白的制备、结构解析、功能机制及治疗应用，均为该领域经典研究或权威综述。
Tumor Necrosis Factor (TNF) recombinant protein is a biologically active molecule produced through genetic engineering techniques, designed to mimic the natural TNF cytokine. First identified in 1975 as a serum factor causing tumor cell necrosis, TNF exists in two primary forms: TNF-α (produced mainly by macrophages) and TNF-β (lymphotoxin), both playing pivotal roles in immune regulation, inflammation, and apoptosis. TNF-α, in particular, gained prominence for its dual role—acting as a key mediator in host defense against pathogens while also contributing to the pathogenesis of autoimmune diseases, chronic inflammation, and cancer when dysregulated.
The development of recombinant TNF proteins became feasible with advances in recombinant DNA technology in the 1980s. By cloning the TNF gene into expression vectors (e.g., E. coli or mammalian cell systems), researchers produced purified, high-purity TNF proteins for experimental and therapeutic applications. Recombinant TNF-α, for instance, has been widely used to study signaling pathways (e.g., NF-κB and MAPK activation), immune cell interactions, and disease mechanisms in models of sepsis, rheumatoid arthritis, and cancer.
Clinically, recombinant TNF initially showed promise in cancer therapy due to its ability to induce tumor necrosis. However, systemic toxicity limited its use, prompting strategies like localized delivery or structural modifications (e.g., PEGylation) to improve safety. Conversely, the discovery of TNF’s pathogenic role in autoimmune disorders led to the development of anti-TNF biologics (e.g., infliximab, adalimumab), which revolutionized treatment for conditions like Crohn’s disease and psoriasis.
Today, TNF recombinant proteins remain essential tools in immunology research and drug development, bridging insights into cytokine biology and therapeutic innovation.
×
